Skip to main content
Equibles
ALT logo

ALT · Altimmune, Inc.

Track ALT — free

Use ALT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.25 +0.16 (+5.02%)
Russell 2000 member Rebalance outlook locked
Market Cap
$604.95M
Shares
194.52M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.09 Open$3.07 Day$3.02–3.10 52W close$2.59–6.18 Avg vol 30d4.7M Short int51.0M · 26.2% float · 11.0d Short vol57% Last earningsAug 12, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Nov 9, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$41,000
Trailing 12 months
Net income (TTM)
−$91.76M
Trailing 12 months
Revenue growth YoY
+420.0%
Year over year
Operating margin
-230,461.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+127.6%
Year over year · more shares
Price change (1Y)
-19.3%
Trailing year
Short interest
26.2%
Latest settlement · 11.0 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Very Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.67
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −16%
below
Price vs 50-day avg +3%
above
RSI (14) 53
neutral
MACD trend Positive
52-week position 14%
near low
Momentum
relative strength
Very Weak
1-month return +1%
trailing
6-month return −19%
trailing
YTD return −14%
this year
Relative strength −31%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+21% holders QoQ · +58 funds added
Insider flow Accumulating
Net +$44.3K over 90 days · 0% sells
Short interest Falling
26.20% of float · ▼ -1.9% MoM · 11.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
211 holders — near 3-yr high, broad support
Squeeze score 70
high risk · 0–100
Fundamentals
Strong
Revenue growth +105%
Y/Y
EPS growth +25%
Y/Y
Free cash flow $-67.5M
Balance sheet $9.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 69%
annualized · 1-yr
Max drawdown −58%
past year
ATR 4.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−16% Bearish
Price vs 50-day avg
+3% Bullish
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
14% Bearish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow Accumulating
+21% holders QoQ · +58 funds added
Insider flow Accumulating
Net +$44.3K over 90 days · 0% sells
Short interest Falling
26.20% of float · ▼ -1.9% MoM · 11.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
211 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $3 · 14% Range high $6
vs 200-day avg -16% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ALT
Altimmune, Inc.
this stock
$604.95M -14.4% +105.0% — 26.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $140.51B +20.8% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.82B +6.7% +20.8% 20.4 2.3%
ARGX
Argenx SE
 $64.16B +22.3% — — 1.9%
MRNA
Moderna, Inc.
 $61.59B +423.1% +4.3% — 13.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
211
% held
78.8%
Net QoQ
+81.8M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
138
View
Short & Settlement
Short Interest Falling
Shares short
51.0M
Days to cover
11.0d
Change
-965.5K sh
View
Short Volume
Short vol %
57%
As of
Sep 1, 2026
Short Total
View
Fails to Deliver
FTD shares
10.5K
Value
$31.6K
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
47.3%
Week of
Jul 27, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$44.3K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$41.0K
Net income (FY)
$-88.1M
EPS diluted
$-1.00
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
15
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

5D 20D 120D MTD YTD
ALT -3.4% +0.7% -18.7% -0.6% -14.4%
SPY -0.5% -1.2% +12.6% -0.7% +11.7%
vs SPY -2.9% +1.9% -31.3% +0.1% -26.1%
Key facts CIK 1326190 CUSIP 02155H200 13F (30d) 174 filings 174 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)